Under construction – not a live service
Sign in
Taking people in FrancePhase 1/2

Tests elironrasib and daraxonrasib in advanced solid tumors with KRAS G12C mutation

Tests two drugs, alone and together, in adults with advanced KRAS G12C-mutated cancers.

Key facts

Who runs it
Revolution Medicines, Inc.
Where
Angers, Bordeaux, Bron, Lille, Lyon, Montpellier, Nantes, and Strasbourg, FranceSee the 8 sitesAlso in 6 other countries, 48 sites
Trial code
Registry title
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Status
Recruiting
Phase
Phase 1/2
People taking part
534 people, planned
Started
14 Nov 2023
Expected to end
Jun 2029
Type of study
Interventional, 3 groups
Treatments tested
  • Elironrasib
  • Daraxonrasib
Record updated
22 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic solid tumors that carry a KRAS G12C mutation and were treated before. Lung, colorectal and pancreatic cancers are included.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced or metastatic solid tumor with a KRAS G12C mutation, not open to treatment meant to remove all of the disease. ECOG performance status 0 or 1.
Earlier treatment
Solid tumors must have been treated before. For one part of the study, lung cancer must have been treated with immunotherapy, chemotherapy and KRAS G12C (OFF) inhibitors. Other solid tumors must not have had KRAS G12C (OFF) inhibitors.
Biomarker or test result
KRAS G12C mutation, documented by pathology.

Main reasons for not taking part

  • Primary central nervous system (CNS) tumors
  • Active brain metastases
  • Known problem of the gut that would change how drugs are absorbed
  • Major surgery within 28 days before treatment
  • Minor procedures not related to the study within 7 days before treatment

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • 18 years of age
  • Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy; Phase 1b Dose Escalation: solid tumors, previously treated; Phase 1b Dose Expansion and Phase 2:; NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors ii. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors
  • ECOG performance status 0 or 1
  • Adequate organ function

Who cannot take part

  • Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment
  • Known impairment of GI function that would alter the absorption
  • Primary central nervous system (CNS) tumors
  • Active brain metastases

Where in France

Also in 6 other countries, 48 sites

  • West Cancer InstituteAngers, FranceContact: Revolution Medicines, Inc.Taking people
  • Institut BergonieBordeaux, FranceContact: Revolution Medicines, Inc.Taking people
  • Hospital Louise PradelBron, FranceContact: Revolution Medicines, Inc.Taking people
  • Oscar Lambret Center of LillleLille, FranceContact: Revolution Medicines, Inc.Taking people
  • Centre Leon BerardLyon, FranceContact: Revolution Medicines, Inc.Taking people
  • Cancer Institute of MontpellierMontpellier, FranceContact: Revolution Medicines, Inc.Taking people
  • CHU NantesNantes, FranceContact: Revolution Medicines, Inc.Taking people
  • Institute of Cancer of StrasbourgStrasbourg, FranceContact: Revolution Medicines, Inc.No longer taking part

About the trial

What the trial wants to find out

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

The 3 groups in the trial

  • Elironrasib MonotherapyTreatment being tested

    Phase 2 only

    Treatment: Elironrasib

  • Daraxonrasib MonotherapyTreatment being tested

    Phase 2 only

    Treatment: Daraxonrasib

  • Daraxonrasib + Elironrasib CombinationTreatment being tested

    Phase 1b and 2

    Treatment: Elironrasib and Daraxonrasib

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors
Plain-language title
Tests elironrasib and daraxonrasib in advanced solid tumors with KRAS G12C mutationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
22 September 2026